- Home
- EICC vs VCEL Comparison
EICC vs VCEL Comparison
Compare EICC & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EICC | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.0B |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | EICC | VCEL |
|---|---|---|
| Price | $25.15 | $37.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.50 |
| AVG Volume (30 Days) | 18.7K | ★ 599.1K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 7.96% | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | ★ 0.55 | 0.25 |
| Revenue | $51,224,692.00 | ★ $258,716,999.00 |
| Revenue This Year | $39.61 | $17.86 |
| Revenue Next Year | $27.28 | $18.55 |
| P/E Ratio | ★ $23.44 | $152.71 |
| Revenue Growth | ★ 68.61 | 14.05 |
| 52 Week Low | $23.75 | $29.24 |
| 52 Week High | $25.25 | $63.00 |
Technical Indicators
Market Signals| Indicator | EICC | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | 51.36 |
| Support Level | $25.05 | $35.53 |
| Resistance Level | $25.26 | $38.09 |
| Average True Range (ATR) | 0.09 | 1.35 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 30.00 | 71.10 |
Price Performance
Historical ComparisonAbout EICC Eagle Point Income Company Inc. 8.00% Series C Term Preferred Stock due 2029
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.